Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:GRCL NASDAQ:SBTX NASDAQ:TRIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$4.27-2.3%$6.17$3.92▼$71.50$7.24M0.8135,472 shs27,443 shsGRCLGracell Biotechnologies$10.25$10.25$1.40▼$10.44$744.95M-0.331.32 million shsN/ASBTXSilverback Therapeutics$7.94-0.9%$8.31$2.80▼$8.97$286.30M0.6337,931 shs2.40 million shsTRILDefiance Trillion Dollar Club Index ETF$19.86$18.12$5.80▼$20.96$2.09B2.081.87 million shsN/AThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-0.68%+0.46%+2.34%-41.73%-78.66%GRCLGracell Biotechnologies0.00%0.00%0.00%0.00%0.00%SBTXSilverback Therapeutics0.00%-7.00%+7.20%-2.04%-35.36%TRILDefiance Trillion Dollar Club Index ETF0.00%0.00%0.00%0.00%+7.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$4.27-2.3%$6.17$3.92▼$71.50$7.24M0.8135,472 shs27,443 shsGRCLGracell Biotechnologies$10.25$10.25$1.40▼$10.44$744.95M-0.331.32 million shsN/ASBTXSilverback Therapeutics$7.94-0.9%$8.31$2.80▼$8.97$286.30M0.6337,931 shs2.40 million shsTRILDefiance Trillion Dollar Club Index ETF$19.86$18.12$5.80▼$20.96$2.09B2.081.87 million shsN/AThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla-0.68%+0.46%+2.34%-41.73%-78.66%GRCLGracell Biotechnologies0.00%0.00%0.00%0.00%0.00%SBTXSilverback Therapeutics0.00%-7.00%+7.20%-2.04%-35.36%TRILDefiance Trillion Dollar Club Index ETF0.00%0.00%0.00%0.00%+7.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.00Hold$200.004,583.84% UpsideGRCLGracell Biotechnologies 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ATRILDefiance Trillion Dollar Club Index ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$2M3.54N/AN/A($28.51) per share-0.15GRCLGracell Biotechnologies$60K12,415.83N/AN/A$2.95 per share3.47SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ATRILDefiance Trillion Dollar Club Index ETF$150K13,903.44N/AN/A$2.56 per share7.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$59.61M-$50.50N/AN/AN/AN/AN/A-257.22%5/15/2026 (Estimated)GRCLGracell Biotechnologies-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/ASBTXSilverback Therapeutics-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/ATRILDefiance Trillion Dollar Club Index ETF-$59.35M$0.6232.04N/AN/AN/A-23.31%-18.66%N/ALatest SBTX, BCAB, GRCL, and TRIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BCABBioAtla-$10.00-$4.22+$5.78-$4.22$1.72 millionN/A3/31/2026Q4 2025BCABBioAtla-$18.00-$8.00+$10.00-$8.00$0.70 million$2.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/AGRCLGracell BiotechnologiesN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ATRILDefiance Trillion Dollar Club Index ETFN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A0.370.37GRCLGracell Biotechnologies0.027.737.73SBTXSilverback TherapeuticsN/A67.8767.87TRILDefiance Trillion Dollar Club Index ETFN/A19.8219.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%GRCLGracell BiotechnologiesN/ASBTXSilverback Therapeutics74.89%TRILDefiance Trillion Dollar Club Index ETF87.15%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.77%GRCLGracell Biotechnologies28.00%SBTXSilverback Therapeutics34.40%TRILDefiance Trillion Dollar Club Index ETF9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla601.66 million1.46 millionOptionableGRCLGracell Biotechnologies31472.68 million52.33 millionNo DataSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableTRILDefiance Trillion Dollar Club Index ETF33105.00 million95.44 millionNo DataSBTX, BCAB, GRCL, and TRIL HeadlinesRecent News About These CompaniesETF Prime: Murphy on the New Faces of the ETF BoomOctober 29, 2025 | etftrends.comEDefiance Trillion Dollar Club Index ETFOctober 21, 2025 | money.usnews.comTidal Trust II - Defiance Trillion Dollar Club Index ETFOctober 16, 2025 | money.usnews.comTrillion-Dollar Inflows: ETFs Become the Market’s New “Pulse”October 16, 2025 | nai500.comNThe Future Of Psychedelic-Inspired Therapeutics: No-Trip NeuroplastogensAugust 14, 2025 | lifescienceleader.comLPfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment ProblemsJuly 1, 2025 | biospace.comBRatio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted RadiotherapeuticsJune 20, 2025 | finance.yahoo.comTrillium Therapeutics Stock Price HistoryMay 26, 2025 | investing.comTTI Consumer Power Tools, Inc. is Seeking an IP ParalegalSeptember 26, 2024 | ipwatchdog.comIAdvances in Drug Discovery & Development 2024September 8, 2024 | technologynetworks.comTWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comGoogle Cloud unveils the Trillium TPU, its most powerful AI processor so farMay 14, 2024 | siliconangle.comSCachet Bicycle shakes off COVIDFebruary 25, 2024 | baytoday.caBRejuvenate your look with a trip to Fourth Avenue Medical AestheticsJanuary 30, 2024 | chch.comCTTI apprehends motorists for illegal removal of clamps, hunt for four others underwayJanuary 30, 2024 | bulawayo24.comBBridgeBio raises $1.25bn, and other biotech financingsJanuary 19, 2024 | pharmaphorum.comPRatio Therapeutics Raises $50M in Series B FinancingJanuary 17, 2024 | precisionmedicineonline.comPLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBTX, BCAB, GRCL, and TRIL Company DescriptionsBioAtla NASDAQ:BCAB$4.27 -0.10 (-2.29%) Closing price 04:00 PM EasternExtended Trading$4.23 -0.04 (-0.94%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Gracell Biotechnologies NASDAQ:GRCLGracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.Silverback Therapeutics NASDAQ:SBTX$7.94 -0.07 (-0.87%) As of 05/14/2026Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Defiance Trillion Dollar Club Index ETF NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
